Tuberculosis News and Research

Latest Tuberculosis News and Research

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

Tuberculosis independently predicts death from lung cancer in the elderly

Tuberculosis independently predicts death from lung cancer in the elderly, according to a new study from researchers in Hong Kong.

21 May 2012

Afghanistan breaks ground on $30M hospital for treatment of TB, AIDS, malaria

"Afghanistan has begun work on a $30 million hospital for the treatment of tuberculosis [TB], a disease that health officials say kills more than 10,000 Afghans every year," VOA's "Breaking News" blog reports.

19 May 2012

Potential public-private partnership aims to bring TB vaccine trials to mines of Southern Africa

GlobalPost's "Global Pulse" blog reports on a potential public-private partnership that aims to bring tuberculosis (TB) vaccine trials to the gold mines of Southern Africa, where, "for every 100,000 workers ..., 3,000 have tuberculosis, and many have often-fatal, drug-resistant strains of TB."

18 May 2012

Tiny filter could fight against tuberculosis

A tiny filter could have a big impact around the world in the fight against tuberculosis. Using the traditional microscope-based diagnosis method as a starting point, a University of Florida lung disease specialist and colleagues in Brazil have devised a way to detect more cases of the bacterial infection.

18 May 2012

MDG Health Alliance introduced at GBCHealth Conference

The MDG Health Alliance, an innovative new private sector organization created and led by eminent business leaders to tackle urgent global health problems, was introduced today in the United States at the GBCHealth Conference.

17 May 2012

U.S. support for Global Fund may be 'America's greatest global health legacy'

"This year marks the 10th anniversary of the Global Fund to Fight AIDS, Tuberculosis and Malaria, the world's most powerful tool in the fight against the three pandemics," Jonathan Klein, co-founder and CEO of Getty Images, Inc., writes in this post in the Huffington Post Blog.

17 May 2012

U.S. HIV assistance through PEPFAR prevented 740,000 deaths between 2004-2008, study shows

"The lives of more than 740,000 people in nine African countries were saved between 2004 and 2008 by the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]," according to a study conducted by Stanford University School of Medicine researchers and published in the Journal of the American Medical Association (JAMA) on Wednesday, HealthDay News reports.

17 May 2012

Third of world carrying TB; Disease could become incurable without action, WHO warns

"A third of the world's population is carrying tuberculosis [TB], and the disease could become incurable if governments fail to act, the World Health Organization (WHO) has warned," noting that a "lack of funding for public health programs, the sale of inaccurate blood tests and the misuse of drugs, particularly in the private health sector, are hampering the fight against the disease and leading to drug resistance," the Independent reports.

15 May 2012

U.S. investment in global health has been successful, deserves continued congressional support

"Over the next few weeks, appropriators will be engaged in the challenging task of evaluating U.S. foreign assistance funding, including how effectively Congress' global health investments are being used," Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation; Molly Joel Coye, interim president and CEO of PATH; Carolyn Miles, president and CEO of Save the Children; and Richard Stearns, president of World Vision, write in this Roll Call opinion piece.

11 May 2012

MSF says additional resources needed to improve ART access in Burma

Medecins Sans Frontieres (MSF), the largest provider of antiretroviral treatment (ART) in Burma, also known as Myanmar, are calling for the gap between the need for and access to ART in the country to be closed, the Guardian reports.

11 May 2012

USAID launches five-year initiative in Nigeria to strengthen HIV, TB services

U.S. Ambassador to Nigeria Terence McCulley on Tuesday in Abuja, Nigeria, launched a five-year, $224 million USAID program, titled Strengthening Integrated Delivery of HIV/AIDS Services (SIDHAS), that aims to "increase access to high-quality comprehensive HIV/AIDS and tuberculosis prevention, treatment, care and related services through improved efficiencies in service delivery," the Daily Trust reports.

10 May 2012

Researchers use clever screening methods to speed vaccine production

Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.

10 May 2012

IDRI, Aeras partner to develop new TB vaccine candidate

Aeras and the Infectious Disease Research Institute (IDRI) announce today a new agreement to conduct joint development activities with respect to IDRI's novel tuberculosis vaccine candidate. This collaboration reflects the missions of the two non-profit product development partnerships to use cutting-edge science to develop products that address critical diseases of underserved populations around the world, including tuberculosis.

10 May 2012

MSU researcher wins Grand Challenges Explorations grant for work on TB

For his work on developing new treatments for tuberculosis, a Michigan State University researcher has been named a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

10 May 2012

VOA News examines South Africa's rural public health sector

VOA News features a five-part series on South Africa's rural public health sector, which the news service writes is "plagued by a high burden of infectious diseases, severe doctor and nurse shortages, lack of medicines and essential medical equipment and incompetent management," resulting in high patient death rates.

8 May 2012

Various combinations of biomarkers are required to unequivocally diagnose specific disease

With a range of diseases, doctors need unique features which they can use to unequivocally identify a patient's illness for an appropriate diagnosis. Scientists therefore search for the biomarkers for an illness or a combination of biomarkers, known as biosignatures, which are as easy as possible to measure.

7 May 2012

Johns Hopkins receives $15 million NIH grant to establish CFAR

Johns Hopkins University has been awarded $15 million over the next five years from the National Institutes of Health to establish the new Center for AIDS Research (CFAR). CFAR will support more than 180 HIV investigators from the University's Bloomberg School of Public Health, the School of Medicine, the School of Nursing and other schools. A major priority for CFAR will be to address Baltimore's HIV epidemic in addition to training new investigators and conducting international research.

5 May 2012

Global Fund completes reorganization of workforce, tightens focus to 20 'high-impact countries'

The Global Fund to Fight AIDS, Tuberculosis and Malaria "is cutting its workforce and tightening its focus on 20 countries hardest hit by AIDS, tuberculosis and malaria," Reuters reports. Gabriel Jaramillo, who took over as general manager of the fund in January, "said in a statement that the fund had completed a reorganization that would rebalance its workforce with 39 percent more people managing grants and 38 percent fewer in support roles," the news service notes.

3 May 2012

SC formulation of Genentech’s ACTEMRA shows promise against RA

Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.

3 May 2012